Over the past decade or so, I’ve watched on with fascination as consumer wearables have evolved from simple fitness accessories into increasingly sophisticated health tools. Smart rings, watches, patches and bands now collect continuous physiological data at a scale no-one could have predicted or imagined just five years ago.
On the surface, this looks like extraordinary progress. And it is.
But from a clinical perspective, working in cardiology, the situation is a little more complex.
The volume of data I see entering the system is growing exponentially. What isn’t growing at the same pace, unfortunately, is clarity around what can be trusted to inform real decisions.
The issue isn’t that wearable data is poor. On the contrary, much of it is technically impressive. The challenge is determining whether it is reliable enough to relieve the review burden, guide care, support reimbursement, or reassure a patient who is worried about their heart rhythm at two o’clock in the morning.
Practically speaking, if clinicians like me can’t trust the signal, neither can the broader healthcare system. And increasingly, neither will patients.
Scale without trust creates friction
Wearables are no longer confined to wellness but are clearly becoming part of the healthcare infrastructure. Regulatory pathways for digital health are evolving to encourage innovation and speed to market, particularly for lower-risk technologies. Reimbursement frameworks for remote physiological monitoring have been updated, and new models like ACCESS are encouraging the adoption of wearables as a standard of care.
In a nutshell, more devices, producing more data, are reaching patients faster than ever before.
Health systems are debating whether this influx is a help or a hassle. Both are true. Continuous monitoring can detect arrhythmias earlier, improve hypertension management, and identify physiological deterioration before hospitalisation becomes necessary. At the same time, unfiltered streams of data can create operational burden, exacerbate provider burnout, and increase patient anxiety.
Clinicians are now being asked to interpret signals from multiple consumer devices, collected under variable conditions, using different sensing technologies and validated to different standards. Distinguishing what is clinically meaningful from what is noise is increasingly part of the job.
And that’s the sticky part.
Healthcare doesn’t lack data, rather it lacks data it can trust at scale.
Why data without trust doesn’t travel
In my experience, physicians aren’t resistant to this type of innovation – they delay adoption because they aren’t sure if they can trust the data. Without establishing trust, clinical adoption is going to be slow or at an impasse.
Three issues crop up time and time again:
Provenance. We need to understand how the signal is captured, how it performs in real-world conditions, and how it behaves across different populations.
Validation. Performance in controlled environments does not automatically translate to dependable use in daily life. Reproducible validation against recognised clinical standards matters.
Accountability. When a data point influences care, responsibility follows. Without transparent validation, clinicians are understandably cautious.
Why trust is becoming so critical
Before a signal can be acceptable, physicians need to understand what it measures, how reliable it is and whether it holds up outside controlled studies. If those questions aren’t answered clearly and credibly, then the data remains purely observational and unactionable. A waste of everyone’s time.
Increasingly, consumers are applying the same logic when deciding which wearable insights they trust.
That’s why “medical-grade” is emerging as a critical differentiator. Take ECG as an example – a signal physicians use every day to diagnose arrhythmias and guide treatment.
Apple’s integration of ECG into the Apple Watch marked an early turning point in the industry. Most recently, WHOOP’s development and launch of its medical-grade device signalled a move beyond performance analytics toward clinical credibility. Similarly, Samsung, widely accepted as a leader in wearable technology, has invested heavily in their wearable devices and is now expanding their offering in healthcare with the acquisition of Xealth. Technology partners including B-Secur and device manufacturers like AliveCor are pushing the envelope in terms of signal quality and disease identification.
Trust must be designed in
Trust can’t be retrofitted at the marketing stage. It needs to be built into the technology at the beginning.
Sensor design including optical and electrodes determines signal fidelity which can affect consistency across different skin types and use conditions. Algorithms can enhance an already reliable signal, but they can’t compensate for poor signal quality at the source.
As consumers age and healthcare shifts toward preventive models, expectations are changing. Older users managing hypertension, atrial fibrillation risk, or cardiometabolic disease are less interested in novelty and more concerned with reliability.
Given trust is becoming a baseline expectation as opposed to premium feature, it needs to be considered at the very outset of wearable device design.
The commercial implication
In an increasingly crowded wearable market, feature expansion is easy to replicate but clinical validation isn’t.
Devices capable of earning clinician trust opens up participation in reimbursement frameworks, health system collaborations, and chronic condition management. They can engage an older demographic with significant purchasing power and clear health motivation.
Devices that can’t demonstrate validated results will remain confined to the wellness tier of the market, competing primarily on price and failing to capture the huge patient population ready to adopt the new technologies that will help them live longer and happier lives.
As reimbursement models expand and regulatory scrutiny increases, the ability to prove clinical trust will move from advantage to expectation.
Trust isn’t only a clinical filter but is fast emerging as the most durable form of differentiation in the wearable industry.
The inflection point
It’s clear that wearable technology is at an exciting inflection point. The industry has proven it can generate data at scale. The question now is whether it can earn the trust required for that data to influence care in a meaningful way.
In my view, the companies that invest early in robust validation, particularly in areas such as ECG, will define the next decade of growth. Those that rely on inferred metrics without robust validation will struggle to cross the threshold into healthcare relevance.
Wearable noise is indeed exploding but in this next phase of the market, trust will determine who scales.
Photo credit: Sitthiphong, Getty Images
Kenneth Civello, MD, MPH, is a clinical cardiologist and cardiac electrophysiologist at Our Lady of the Lake Hospital. His work focuses on cardiovascular disease and heart rhythm disorders, emphasizing risk detection, remote monitoring, and using AI and wearable technology to extend care beyond the clinic. His research centers on digital health tools, remote physiologic monitoring programs, and AI platforms that convert continuous patient data into actionable clinical insight.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
